Navigation Links
Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators
Date:10/6/2010

TORONTO, Oct. 6 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, growth in the $2 billion US cardiac resynchronization therapy defibrillator market will be supported by the expanded approval of Boston Scientific's chronic resynchronization therapy defibrillators in New York Heart Association class I and II patients.

The New York Heart Association classification system ranks heart failure patients according to different levels of severity, with Class I being the least severe and Class IV the most severe. Classes I and II are considered mild forms of heart failure with relatively minor symptoms.  Classes III and IV are considered to be moderate and severe forms of heart failure, and Class IV patients experience discomfort at rest and very little physical activity.

Cardiac resynchronization therapy defibrillator procedures will grow due to results from the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. MADIT-CRT was a randomized trial designed to compare patients in New York Heart Association Class I or II who received a cardiac resynchronization therapy defibrillator with those who received an implantable cardioverter defibrillator; the trial found patients who received a cardiac resynchronization therapy defibrillator had a 34% reduction in the risk of heart failure or death.

"As a result of this trial, in March 2010, an FDA panel of cardiologists voted in favor of expanding the indication of cardiac resynchronization therapy defibrillators to include mild heart failure patients, increasing the potential patient pool," says Julie McLaughlin, Analyst at MRG.  "This decision was upheld in September 2010 when the FDA expanded the indication for Boston Scientific's cardiac resynchronization therapy defibrillator devices to include high risk New York Heart Association Class I and II patients.  This makes Boston Scientific the only manufacturer with cardiac resynchronization therapy defibrillator devices approved for all types of NYHA classes of heart failure."

MRG's Global Markets for Cardiac Rhythm Management Devices 2011 report provides critical insight into trends that will fuel and limit market growth for cardiac rhythm management devices in the US, Europe (France, Germany, Italy, and the UK), and Japan. The report includes a breakdown of unit volumes, average selling prices, and market values for pacemakers (single-chamber, dual-chamber, and cardiac resynchronization therapy pacemakers) and implantable defibrillators (single-chamber, dual-chamber, and cardiac resynchronization therapy defibrillators).

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101akrohn@mrg.netChris ComfortDecision Resources, Inc. 781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
2. Enobia Reports Positive Results For Phase II Trial of ENB-0040 in Juvenile Hypophosphatasia
3. Dynatronics Announces Positive Year-end Results
4. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
5. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
6. ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmins Potential to Transform the Treatment of Retinal Disorders
7. Bionovo Receives Positive Guidance from FDA on Menerba®
8. OXIS International, Inc. Announces Publication of Positive Results of Ergothioneine Safety Study in the Journal TOXICOLOGY
9. Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
10. Excaliard Announces Positive Data From Phase 2 Clinical Trial of Its Anti-Scarring Drug, EXC 001
11. Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 ... Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria ... of the Primary Hyperoxaluria (Genito Urinary System And ... a rare condition characterized by recurrent kidney and ... a substance called oxalate. Symptoms include blood in ...
(Date:3/23/2017)... , March 23, 2017  Digital Pharmacist ... ), a rapidly growing digital health company, ... mobile app that allows patients to manage their ... locations such as Denver Health Pharmacy, USave Pharmacy ... acquisition helps Digital Pharmacist accelerate its product development ...
(Date:3/23/2017)... -- Ethicon* today announced the completion of its acquisition ... device company that manufactures and markets the LINX™ ... Gastroesophageal Reflux Disease (GERD). This acquisition is aligned ... minimally invasive options for patients suffering from prevalent ... transaction have not been disclosed. ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... March is ... that pack a punch when it comes to maintaining good health. Every day, two ... minutes, your kidneys filter every drop of your blood, eliminating waste, regulating fluid levels ...
(Date:3/23/2017)... ... ... The TouchPoint Solution, home of Buzzies *, is boosting the Arizona economy ... change the way we interact with stress and live our day-to-day lives,” said Dr. ... December 2016, The TouchPoint Solution has sold more than $750,000 in product sales. The ...
(Date:3/23/2017)... ... 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: ... Salka , 43rd President of the United States of America: George W. Bush ... and Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: ...
(Date:3/23/2017)... ... , ... It’s that time of year again! Time to think about summer ... , which can be frustrating when they don’t even know how to begin describing ... public relations firm outside of Philadelphia, have offered these three tips to make the ...
Breaking Medicine News(10 mins):